Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance Expects U.S. Approval Within 90 Days for Evolysse Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels ™ Provides 2025 Guidance and Maintains Projection for Full-Year 2025 Profitability 1 NEWPORT BEACH, Calif., January 21, 2025 – Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today announced ...

Evolus, Inc. (EOLS) shares rallied 5.5% in the last trading session to close at $15.04. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 41.6% gain over the past four weeks.Evolus recorded a strong price increase after it announced the receipt of the FDA’s approval for Evolysse Form and Evolysse Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse collection. These approvals mark ...

Evolus, Inc. (EOLS) shares rallied 28.3% in the last trading session to close at $13.48. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3% loss over the past four weeks.The sharp upsurge in EOLS shares can be attributed to positive market sentiment surrounding the company’s impressive preliminary results and strong growth outlook. Evolus reported a strong preliminary Q4 2024 performance, posting $79 million ...

Group 1: Investment Opportunities and Resources - The Haggerston BioHealth marketplace channel offers at least 4 exclusive stock tips weekly, focusing on Pharma, Biotech, and Healthcare sectors [1] - The channel provides access to a model portfolio, investment bank-grade financial models, and research for investors [1] - The group caters to both novice and experienced biotech investors, offering catalysts, buy/sell ratings, product sales forecasts, integrated financial statements, discounted cash flow analysis, and market-by-market analysis [2] Group 2: Expertise and Background - Edmund Ingham, a biotech consultant with over 5 years of experience covering biotech, healthcare, and pharma, leads the Haggerston BioHealth investing group [2] - He has compiled detailed reports on over 1,000 companies in the biotech, healthcare, and pharma sectors [2]

The price trend for Evolus, Inc. (EOLS) has been bearish lately and the stock has lost 11.5% over the past week. However, the formation of a hammer chart pattern in its last trading session indicates that the stock could witness a trend reversal soon, as bulls might have gained significant control over the price to help it find support.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that mak ...

A downtrend has been apparent in Evolus, Inc. (EOLS) lately with too much selling pressure. The stock has declined 29.8% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for sp ...

Evolus, Inc. (NASDAQ:EOLS) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Nareg Sagherian - VP and Head of Global IR and Corporate Communications David Moatazedi - President and CEO Rui Avelar - Chief Medical Officer and Head of R&D Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Navann Ty - BNP Paribas Doug Tsao - H.C. Wainwright Operator Good afternoon, everyone, and thank you for standing by. Welcome to Evolus Third Quarter 2024 Earnings Confere ...

Evolus, Inc. (EOLS) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -137.50%. A quarter ago, it was expected that this company would post a loss of $0.04 per share when it actually produced a loss of $0.07, delivering a surprise of -75%.Over the last four quarters, the company has not been ab ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _______ ...

Evolus Reports Third Quarter 2024 Results • Total Net Revenue of $61.1 Million for Q3 2024, Up 22% from Q3 2023; Year-To-Date Growth of 33% • Received Approval for Estyme Injectable Hyaluronic Acid (HA) Gels in the European Union; Experience Program to Launch Immediately with Full Launch Expected in the Second Half of 2025 • Premarket Approval (PMA) Application for Evolysse™ Form and Evolysse™ Smooth Injectable HA Gels Currently Under Review by the U.S. Food and Drug Administration (FDA) with Approval and L ...